Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer.
Glomeruloid microvascular proliferation (GMP) in breast cancer independently adversely affected survival (relative risk 1.9, 95% CI: 1.2-3.0), particularly among women who received adjuvant chemotherapy (10-year survival 27 vs 69%, P=0.0003), and was significantly associated with p53 overexpression and BRCA1 germline mutations. The presence of GMP may influence treatment decisions.
Goffin
J R
JR
Tufts University Department of Medicine, Division of Hematology/Oncology, Tufts-New England Medical Center, 750 Washington St., Tufts-NEMC #245 Boston, MA 02111, USA.
Straume
O
O
Chappuis
P O
PO
Brunet
J-S
JS
Bégin
L R
LR
Hamel
N
N
Wong
N
N
Akslen
L A
LA
Foulkes
W D
WD
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000098:blood supply* / Q000378:metabolism*; D002455:Cell Division; D004730:Endothelium, Vascular / Q000473:pathology; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D018095:Germ-Line Mutation; D006801:Humans; D007124:Immunoenzyme Techniques; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009367:Neoplasm Staging; D009389:Neovascularization, Pathologic / Q000473:pathology*; D011379:Prognosis; D015996:Survival Rate; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*
D016159:Tumor Suppressor Protein p53